Study identifier:D9090C00007
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:2024-513142-11-00
Phase Ib Randomised, Placebo-controlled, Double-blind, Multicentre Study to Assess the Effects and Safety of AZD5462 on top of Dapagliflozin in Participants with Heart Failure and Moderate Renal Impairment
Renal Impairment
Phase 1
No
AZD5462, Dapagliflozin
All
40
Interventional
18 Years - 85 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
PAREXEL
No locations available
Arms | Assigned Interventions |
---|---|
Active Comparator: AZD5462 + dapagliflozin Participants will receive AZD5462 on top of dapagliflozin once daily. | Drug: AZD5462 Participants will receive AZD5462 on top of dapagliflozin once daily. Drug: Dapagliflozin Participants will receive dapagliflozin once daily with AZD5462 or placebo. |
Placebo Comparator: Placebo + dapagliflozin Participants will receive placebo on top of dapagliflozin once daily. | Drug: Dapagliflozin Participants will receive dapagliflozin once daily with AZD5462 or placebo. Other: Placebo Participants will receive placebo on top of dapagliflozin once daily. |